These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1329748)

  • 21. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
    Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
    Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
    Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
    Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
    Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
    Takeda S; Shimazoe T; Sato K; Sugimoto Y; Tsuruo T; Kono A
    Biochem Biophys Res Commun; 1992 Apr; 184(2):618-25. PubMed ID: 1315526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
    Chang JY; Guo X; Chen HX; Jiang Z; Fu Q; Wang HK; Bastow KF; Zhu XK; Guan J; Lee KH; Cheng YC
    Biochem Pharmacol; 2000 Mar; 59(5):497-508. PubMed ID: 10660116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
    J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
    Khageh Hosseini S; Kolterer S; Steiner M; von Manstein V; Gerlach K; Trojan J; Waidmann O; Zeuzem S; Schulze JO; Hahn S; Steinhilber D; Gatterdam V; Tampé R; Biondi RM; Proschak E; Zörnig M
    Biochem Pharmacol; 2017 Dec; 146():53-62. PubMed ID: 29031818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
    Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
    Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
    Saga Y; Mizukami H; Suzuki M; Kohno T; Urabe M; Ozawa K; Sato I
    Clin Cancer Res; 2002 May; 8(5):1248-52. PubMed ID: 12006545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
    Okamoto R; Takano H; Okamura T; Park JS; Tanimoto K; Sekikawa T; Yamamoto W; Sparreboom A; Verweij J; Nishiyama M
    Jpn J Cancer Res; 2002 Jan; 93(1):93-102. PubMed ID: 11802813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
    Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
    Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
    Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
    Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
    Sadzuka Y; Hirotsu S; Hirota S
    Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
    Katschinski DM; Robins HI
    Int J Cancer; 1999 Jan; 80(1):104-9. PubMed ID: 9935239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
    Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
    Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.